Please login to the form below

Not currently logged in
Email:
Password:

asfotase alfa

This page shows the latest asfotase alfa news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still ... However, its 2015 takeover of Synageva for $8.4bn has been less

Latest news

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    New draft guidance from NICE means that the wider population of infants with HPP - not just those with the most severe form - will be eligible for treatment with Strensiq (asfotase alfa), ... NICE also turned down Alexion's other new enzyme replacement

  • NICE blocks second Alexion rare disease drug in a week NICE blocks second Alexion rare disease drug in a week

    The verdict comes just days after the agency excluded two patient groups in its final determination on rare bone disorder drug Strensiq (asfotase alfa), giving the go-ahead only for perinatal- ... Throughout this extremely complicated evaluation we have

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    Janssen. MCL, CLL, WM. sebelipase alfa. Kanuma. Alexio. Lysosomal acid lipase deficiency (LAL-D). ... asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    These were Kanuma (sebelipase alfa), the first-ever treatment for the rare, inherited disorder lysosomal acid lipase deficiency - and Strensiq (asfotase alfa), the first enzyme replacement therapy for patients with infantile- ... Alkermes. USA. asfotase

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    Strensiq (asfotase alfa) is an enzyme replacement therapy that is designed to address the underlying deficiency in HPP, which leads to weakening of bones, chronic pain and muscle weakness and other

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics